Siret Tahk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Siret Tahk has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anja Wittner
Ludwig-Maximilians-Universität München 2 Gene Center and Department of Biochemistry Munich, Germany
17 shared publications - Fabian Schuurmans
Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands
17 shared publications - Gosse J. Adema
Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands
17 shared publications - Karl-Peter Hopfner
Gene Center, Department of Biochemistry, Ludwig-Maximilians-Universität München, Munich, Germany
17 shared publications - Matthia G.M. Boros
Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands
17 shared publications - Renske J.E. van Den Bijgaart
Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands
17 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from In Vivo Analysis of Neuroblastoma Targeting Potential of aGD2–SIRPα Fusion Antibodies for Local CD47 Blockade
Anti-GD2 monoclonal antibodies (aGD2 mAbs) are the standard immunotherapy for patients with high-risk neuroblastoma. This treatment has improved 5-year overall survival; however, long-term efficacy still requires improvement. The “don’t eat me” signal CD47 is upregulated on neuroblastoma tumor cells and inhibits aGD2 mAb effector mechanisms. Although GD2 is restrictively expressed on neuroblastoma tumor cells, CD47 expression is ubiquitous, resulting in an antigen sink and on-target off-tumor–related cytotoxicities. Recently, we developed two aGD2–SIRPα fusion mAbs for the murine and human settings. In vitro, these aGD2–SIRPα fusion mAbs restrict CD47 blockade toward GD2+ neuroblastoma tumor cells. In this study, we explored the tumor-targeting ability of aGD2–SIRPα fusion mAbs in a syngeneic 9464D-Luc-GFP and SK-N-AS xenograft neuroblastoma tumor model. Conventional aCD47 and aSIRPα mAbs encountered a dominant antigen sink in the 9464D-Luc-GFP model. Surprisingly, although aGD2 mAbs preferentially targeted tumors, murine aGD2–mSIRPα fusion mAbs accumulated in similar organs as aCD47 mAbs. Binding analysis of murine aGD2–mSIRPα and human aGD2–hSIRPα fusion mAbs to red blood cells (RBC) revealed strong binding of murine aGD2–mSIRPα to RBCs, whereas their human counterparts showed negligible binding. These data indicate species-specific CD47–SIRPα binding patterns. Utilizing a SK-N-AS xenograft model, we show effective tumor targeting of the human aGD2–hSIRPα fusion mAbs with hSIRPα in a C-terminal configuration. These data provide the first proof of principle for neuroblastoma tumor–targeted blockade of CD47 by aGD2–hSIRPα fusion mAbs in vivo and support the further development of aGD2–hSIRPα mAbs as attractive therapeutics to improve aGD2-based neuroblastoma immunotherapy.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from In Vivo Analysis of Neuroblastoma Targeting Potential of aGD2–SIRPα Fusion Antibodies for Local CD47 Blockade
Anti-GD2 monoclonal antibodies (aGD2 mAbs) are the standard immunotherapy for patients with high-risk neuroblastoma. This treatment has improved 5-year overall survival; however, long-term efficacy still requires improvement. The “don’t eat me” signal CD47 is upregulated on neuroblastoma tumor cells and inhibits aGD2 mAb effector mechanisms. Although GD2 is restrictively expressed on neuroblastoma tumor cells, CD47 expression is ubiquitous, resulting in an antigen sink and on-target off-tumor–related cytotoxicities. Recently, we developed two aGD2–SIRPα fusion mAbs for the murine and human settings. In vitro, these aGD2–SIRPα fusion mAbs restrict CD47 blockade toward GD2+ neuroblastoma tumor cells. In this study, we explored the tumor-targeting ability of aGD2–SIRPα fusion mAbs in a syngeneic 9464D-Luc-GFP and SK-N-AS xenograft neuroblastoma tumor model. Conventional aCD47 and aSIRPα mAbs encountered a dominant antigen sink in the 9464D-Luc-GFP model. Surprisingly, although aGD2 mAbs preferentially targeted tumors, murine aGD2–mSIRPα fusion mAbs accumulated in similar organs as aCD47 mAbs. Binding analysis of murine aGD2–mSIRPα and human aGD2–hSIRPα fusion mAbs to red blood cells (RBC) revealed strong binding of murine aGD2–mSIRPα to RBCs, whereas their human counterparts showed negligible binding. These data indicate species-specific CD47–SIRPα binding patterns. Utilizing a SK-N-AS xenograft model, we show effective tumor targeting of the human aGD2–hSIRPα fusion mAbs with hSIRPα in a C-terminal configuration. These data provide the first proof of principle for neuroblastoma tumor–targeted blockade of CD47 by aGD2–hSIRPα fusion mAbs in vivo and support the further development of aGD2–hSIRPα mAbs as attractive therapeutics to improve aGD2-based neuroblastoma immunotherapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 3 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 3 shows the gating strategy used for the BMDM phagocytosis assay, phagocytosis of the 9464D parental cell line, representative images showing EL4-GD2 phagocytosis using life cell imaging and quantification of maximum phagocytosis levels derived from dose-response curves.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 3 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 3 shows the gating strategy used for the BMDM phagocytosis assay, phagocytosis of the 9464D parental cell line, representative images showing EL4-GD2 phagocytosis using life cell imaging and quantification of maximum phagocytosis levels derived from dose-response curves.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary table 2 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary table 2 shows the complete amino acid sequences of the aGD2(-SIRPα fusion) mAbs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 2 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary table 2 shows the complete amino acid sequences of the aGD2(-SIRPα fusion) mAbs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Neuroblastoma is a childhood malignancy characterized by overexpression of disialoganglioside GD2. Treatment with anti-GD2 monoclonal antibodies (aGD2 mAb) has prolonged the survival of patients with neuroblastoma; however, long-term efficacy needs further improvement. Neuroblastoma tumor cells upregulate expression of the innate immune checkpoint and do not eat me signal CD47 to evade immune recognition and phagocytosis by signal regulatory protein alpha (SIRPα)-expressing myeloid cells. Targeting of CD47 remains challenging because ubiquitous CD47 expression on healthy cells causes on-target off-tumor related toxicities and functions as an antigen sink. To locally restrict CD47 blockade to the neuroblastoma tumor site, we successfully developed aGD2–SIRPα fusion mAbs for the murine and human setting. These fusion mAbs are equipped with a functional Fc-domain and the extracellular SIRPα domain 1 either fused to the N-terminus of the light chain or to the C-terminus of the heavy chain. Both aGD2–SIRPα fusion mAbs selectively bind neuroblastoma tumor cells and provide GD2-dependent SIRPα domain–mediated CD47 blockade. Furthermore, they potently induce innate immune effector mechanisms through the interaction of the mAbs Fc-domain with Fcγ receptors. Functional analysis of the fusion mAbs demonstrated enhanced phagocytosis and NK cell–mediated killing of neuroblastoma tumor cells compared with the conventional aGD2 mAb. In addition, these novel antibodies modulate the cytokine production by primary macrophages. The aGD2–SIRPα fusion mAbs outperformed aGD2 mAb across a broad range of CD47/GD2 coexpressing tumor cells. This research shows the successful development of aGD2–SIRPα fusion mAbs to provide targeted blockade of CD47 for the treatment of solid neuroblastoma tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Neuroblastoma is a childhood malignancy characterized by overexpression of disialoganglioside GD2. Treatment with anti-GD2 monoclonal antibodies (aGD2 mAb) has prolonged the survival of patients with neuroblastoma; however, long-term efficacy needs further improvement. Neuroblastoma tumor cells upregulate expression of the innate immune checkpoint and do not eat me signal CD47 to evade immune recognition and phagocytosis by signal regulatory protein alpha (SIRPα)-expressing myeloid cells. Targeting of CD47 remains challenging because ubiquitous CD47 expression on healthy cells causes on-target off-tumor related toxicities and functions as an antigen sink. To locally restrict CD47 blockade to the neuroblastoma tumor site, we successfully developed aGD2–SIRPα fusion mAbs for the murine and human setting. These fusion mAbs are equipped with a functional Fc-domain and the extracellular SIRPα domain 1 either fused to the N-terminus of the light chain or to the C-terminus of the heavy chain. Both aGD2–SIRPα fusion mAbs selectively bind neuroblastoma tumor cells and provide GD2-dependent SIRPα domain–mediated CD47 blockade. Furthermore, they potently induce innate immune effector mechanisms through the interaction of the mAbs Fc-domain with Fcγ receptors. Functional analysis of the fusion mAbs demonstrated enhanced phagocytosis and NK cell–mediated killing of neuroblastoma tumor cells compared with the conventional aGD2 mAb. In addition, these novel antibodies modulate the cytokine production by primary macrophages. The aGD2–SIRPα fusion mAbs outperformed aGD2 mAb across a broad range of CD47/GD2 coexpressing tumor cells. This research shows the successful development of aGD2–SIRPα fusion mAbs to provide targeted blockade of CD47 for the treatment of solid neuroblastoma tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 1 shows the schematical configuration of the aCD33-SIRPα fusion and aGD2(-SIRPα fusion) mAbs, purification of aCD33-SIRPa fusion mAbs and thermal stability of the aGD2(-SIRPα fusion) mAbs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Development of aGD2–SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47
Supplementary Fig. 1 shows the schematical configuration of the aCD33-SIRPα fusion and aGD2(-SIRPα fusion) mAbs, purification of aCD33-SIRPa fusion mAbs and thermal stability of the aGD2(-SIRPα fusion) mAbs.